Home » Newsletters » BioWorld Science

BioWorld Science

March 3, 2009

View Archived Issues

Autoantigen insulin vaccine shows potential in newly diagnosed type 1 diabetes mellitus

OSU-HDAC42 shows potency in in vivo and in vitro models of bladder cancer

Amicus suspends enrollment for phase II AT-2220 trial in Pompe disease

Faes Farma seeks approval for bilastine in 29 European countries

Abbott scientists describe new anticancer Sp1 inhibitors in recent patent

FDA issues complete response letter regarding Traclee sNDA

Novel VEGFR-3 (FLT4) inhibitors prepared and tested at sanofi-aventis

AstraZeneca claims novel JAK2 inhibitors with potential as anticancer agents

Nektar reports positive results from phase II oral NKTR-118 study

Astellas and XenoPort announce results from phase II ASP-8825/XP-13512 trial

Aerovance initiates phase IIb Aerovant trial for uncontrolled asthma

Eribulin active in phase II study in castration-resistant prostate cancer patients

Serlopitant effective but less so than tolterodine in overactive bladder

AGS-PSCA treatment refined in phase Ib study in prostate cancer

BioAlliance Pharma reacquires European rights to Loramyc

Endo licenses axomadol and returns rights to Transdur-sufentanil

Merck & Co. commences phase II study of oral deforolimus under Ariad collaboration

FDA approves Pluristem's IND application to initiate phase I clinical trial of PLX-PAD

Intranasal Therapeutics changes name to Ikano Therapeutics and completes series B financing

Hi-Tech Pharmacal acquires ECR Pharmaceuticals for USD 5.1 million

Xencor and Pfizer sign technology licensing agreement for Xtend and XmAb

Marinus presents successful results from phase II ganaxolone trial

New EphB4 inhibitors reported in recent AstraZeneca patents

Auxilium submits BLA for Xiaflex for Dupuytren's contracture

New Hsp90 inhibitors reported in recent patent from Merck KGaA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...